Posts Tagged ‘treatment’
Prostate Cancer and ‘Expectant Management’
Prostate cancer (PCa) is a type of cancer that develops in the prostate cells of the male reproductive system. The cancer is the 2nd most common type of cancer for men after skin cancer. It can be treated successfully. Prostate cancer in the early stages has no symptoms and is often found as a result of testing by such tests as PSA and ultrasound. Expectant management is a combination of the standard watch and wait (for symptoms to appear) and active surveillance through scheduled testing and doctor’s examinations.
Most recently at the 2014 Genitourinary Cancers Symposium, researchers reported expectant management for low-risk prostate cancer is on the rise. Matthew J. Maurice, MD, a urology resident at University Hospitals Case Medical Center in Cleveland, and colleagues used the National Cancer Database to identify 287,562 men diagnosed with low-risk PCa from 2004 to 2011. Of these, 34,132 are receiving expectant management (EM). The investigators observed a significant and steady rise in EM usage beginning in 2008. Compared with patients diagnosed in 2004, those diagnosed in 2011 had a significant 2.5 times increased odds of receiving EM, the study found. Aside from year of diagnosis, older age and higher Charlson co-morbidity scores predicted increased use of EM usage.
Type of hospital and type of insurance types also predicted EM use, “calling into question whether non-clinical factors are influencing EM selection,” the authors concluded in a poster presentation. Patients treated at comprehensive cancer centers had a significant 37% decreased likelihood of receiving EM than patients treated at community hospitals. Additionally, patients with private health insurance had a significant 10% decreased likelihood of receiving EM compared with those who have publicly funded health coverage.
There may be financial disincentives for healthcare systems or healthcare providers to offer EM, as this approach is known to cost less – and presumably, reimburse less – than initial active treatment, he said.
Prostate Cancer and Diabetes
There are many factors related to the development of prostate cancer including genetics, diet, and overall health. According to Health Day, a study conducted of nearly 4,000 diabetic men diagnosed with prostate cancer found those using metformin were less likely to die of the cancer than other causes when compared to men using other diabetes drugs. Although the drug is used to treat cancer patients with diabetes, research suggests metformin may reduce the risk of prostate cancer.
Anti-Inflammatory Diet Could Prevent Prostate Cancer
New research is showing that an anti-inflammatory diet may prevent prostate cancer in men, and improve the chances of surviving prostate cancer in men already diagnosed with the disease. Dr. Angelo De Marzo of Johns Hopkins Medicine has found that prostate cells transitioning from normal to cancerous enter an “in-between” state that exhibit significant signs of inflammation. Many ongoing studies are attempting to determine the link between inflammation and prostate cancer, but there is significant evidence that obesity increases inflammation as well as increasing the risk of high-grade, aggressive prostate tumors.
An anti-inflammatory diet is likely to reduce body weight, and research is showing that it also lowers the risk of dying from prostate cancer. Of 4,577 men in a non-metastatic prostate cancer study, .those who consumed the highest amount of “healthy” fats had the lowest risk of developing metastatic cancer. Men who ate large amounts of animal fats and trans fats had the highest risk of death.
For more information on anti-inflammatory diets and prostate cancer, please visit the Prostate Cancer Foundation.
To learn about foods that constitute an anti-inflammatory diet, please visit Dr. Andrew Weil’s Anti-Imflammatory Food Pyramid.
Prostate Cancer and Obesity
According to a recent study released at the Canadian Urological Association’s annual meeting, men with obesity may increase the long-term risk of disease progression for low-risk prostate cancer. The study examined 565 patients with low-risk prostate cancer. Patients endured different forms of testing from digital rectal examinations (DRE) to PSA testing every three months.
The study found 22% of those examined were obese with a body mass index of 30 or greater. Additionally, the study analyzed the pathologic progression and therapeutic progression in 30% of the men tested.
Overall, the study found that obesity is a risk factor for prostate cancer, according to Dr. Bimal Bhindid, head researcher from the University of Toronto.
What To Do?
Urologists like Dr. Snoy can provide prostate cancer screenings and treatment recommendations. If you believe you or a loved one is at risk for prostate cancer and would like to inquire about a screening, please contact our office for an appointment.